摘要
目的探讨鳞状细胞癌抗原(SCC)、癌胚抗原(CEA)、糖类抗原125(CA125)联合检测在肺癌早期诊断中的临床应用效果。方法采用全自动化化学发光免疫分析仪对早期肺癌患者、肺部良性疾病患者及健康体检者血清SCC、CEA及CA125浓度进行测定。结果肺癌组3项肿瘤标志物浓度显著高于良性疾病组及对照组(P<0.05);腺癌患者CEA和CA125测定浓度均显著高于鳞癌和小细胞癌患者(P<0.05),鳞癌患者SCC测定浓度明显高于腺癌及小细胞肺癌患者(P<0.05);3项肿瘤标志物联合检测的灵敏度、特异度、阳性预测值和阴性预测值均显著优于单项检测,差异有统计学意义(P<0.05)。结论 SCC、CEA及CA125联合检测可用于肺癌早期诊断,具有推广价值。
Objective To explore the clinical application effect of squamous cell carcinoma antigen（SCC）,cancer embryo antigen（CEA）and carbohydrate antigen 125（CA125）chemiluminescence combined detection in early diagnosis of lung cancer.MethodsThe SCC,CEA and CA125 levels in the patients with early stage lung cancer,benign lung diseases and healthy subjects undergoing physical examination were detected by using the automatic chemiluminescence immune analyzer.Results The concentrations of three tumor markers in the lung cancer group were significantly higher than those in the benign disease group and control group（P〈0.05）;t he concentrations of CEA and CA125 in the adenocarcinoma patients with were significantly higher than those in the patients with squamous cell carcinoma and small cell carcinoma（P〈0.05）.The concentration of SCC in the patients with squamous cell carcinoma was significantly higher than that in the patients with adenocarcinoma and small cell lung cancer（P〈0.05）.The sensitivity,specificity,positive predictive value and negative predictive value of combined detection of three tumor markers were significantly better than that of single tumor marker,and the difference was statistically significant（P〈0.05）.Conclusion The combined detection of SCC,CEA and CA125 can be used in the early diagnosis of lung cancer and has the promotion value.
出处
《国际检验医学杂志》
CAS
2017年第5期611-612,共2页
International Journal of Laboratory Medicine
